Compare GROW & ACET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GROW | ACET |
|---|---|---|
| Founded | 1968 | 1947 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 33.0M | 33.5M |
| IPO Year | 1995 | 2017 |
| Metric | GROW | ACET |
|---|---|---|
| Price | $2.67 | $3.20 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $34.83 |
| AVG Volume (30 Days) | 12.1K | ★ 195.4K |
| Earning Date | 11-16-2026 | 11-13-2026 |
| Dividend Yield | ★ 3.36% | N/A |
| EPS Growth | ★ 900.00 | N/A |
| EPS | ★ 0.24 | N/A |
| Revenue | ★ $14,399,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $11.22 | ★ N/A |
| Revenue Growth | ★ 32.77 | N/A |
| 52 Week Low | $2.23 | $0.46 |
| 52 Week High | $3.65 | $9.97 |
| Indicator | GROW | ACET |
|---|---|---|
| Relative Strength Index (RSI) | 42.19 | 20.08 |
| Support Level | $2.49 | N/A |
| Resistance Level | $2.75 | $9.51 |
| Average True Range (ATR) | 0.10 | 0.31 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 37.14 | 5.53 |
US Global Investors Inc is a registered investment advisory firm. The company manages the following business segments: Investment management services; through which the company offers, to U.S. Global Investors Funds (USGIF or the Funds) and exchange-traded fund (ETF) clients, a range of investment management products and services to meet the needs of individual and institutional investors; and Corporate Investments, through which the company invests for its own account in an effort to add growth and value to its cash position. It derives all its revenue from Investment management services.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. It is advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. The company's main product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, and is being developed for the potential treatment of autoimmune diseases. Additionally, it is pursuing ADI-212, a next-generation gene-edited and armored clinical candidate designed to target prostate-specific membrane antigen (PSMA).